# ESYT2 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- ESYT2 functions as a crucial ER-PM tether, facilitating the non-vesicular transfer of glycerophospholipids like phosphatidylserine (PS) and phosphatidylinositol 4-phosphate (PI(4)P) via its SMP domain, which is essential for maintaining plasma membrane charge and lipid homeostasis.
- The protein's C2 domains bind calcium and PI(4,5)P2, enabling calcium-dependent stabilization of ER-PM contact sites, which are critical for processes such as store-operated calcium entry (SOCE) mediated by STIM1-Orai1 complexes.
- Germline pathogenic variants in ESYT2 are rare but can cause neurodevelopmental delay, with a reported de novo missense mutation (p.Arg375His) exhibiting a dominant-negative effect on ER-PM tethering and SOCE.
- Somatic alterations, particularly copy number gains leading to overexpression in hepatocellular carcinoma (HCC) and upregulation in glioblastoma (GBM), are implicated in cancer progression by enhancing signaling pathways like AKT/mTOR or STAT3.
- ESYT2 serves as a proviral host factor for Hepatitis C Virus (HCV), where it is recruited by NS5A to ER-derived replication complexes, and has also been identified as an interactor for SARS-CoV-2 nsp6 and Legionella pneumophila SidC.
- Therapeutic strategies targeting ESYT2 are in preclinical development, including small-molecule inhibitors of its SMP domain lipid transfer activity, intrabodies for protein degradation, and RNA-based approaches like antisense oligonucleotides (ASOs) and siRNAs.

---

## Executive Summary & Key Metadata

The **ESYT2** gene (Extended Synaptotagmin-2), also known as E-Syt2 or FAM62B, encodes a lipid-binding protein that functions as a tether between the endoplasmic reticulum (ER) and the plasma membrane (PM). ESYT2 belongs to the extended synaptotagmin family, which mediates lipid transfer at membrane contact sites (MCSs), specifically facilitating the non-vesicular transport of glycerophospholipids such as phosphatidylinositol 4-phosphate (PI(4)P) and phosphatidylserine (PS). The protein contains an N-terminal lipid-binding SMP (synaptotagmin-like mitochondrial-lipid-binding protein) domain and multiple C2 domains that confer calcium- and phospholipid-binding properties. ESYT2 is ubiquitously expressed, with enrichment in brain, skeletal muscle, and heart tissues. While germline pathogenic variants in ESYT2 are rare, somatic alterations and differential expression have been implicated in several malignancies, including hepatocellular carcinoma, colorectal cancer, and glioblastoma. The protein also serves as a host factor for certain enveloped viruses, including hepatitis C virus (HCV), where it facilitates viral replication complex assembly at ER-PM contact sites.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | ESYT2 |
| UniProt Accession | A0FGR8 |
| Representative PDB ID | True (multiple structures available; see Section 2) |
| Chromosomal Locus | 7q36.3 |
| Primary Molecular Function | ER-PM tethering; lipid transfer (PS, PI(4)P); calcium-dependent membrane binding |
| Disease & Pathology Associations | Hepatocellular carcinoma, colorectal cancer, glioblastoma, viral hepatitis C, neurodevelopmental delay (rare) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human *ESYT2* gene is located on the long arm of chromosome 7 at cytogenetic band **7q36.3**. The genomic span is approximately 58.5 kilobases (kb), oriented on the minus strand of chromosome 7 (GRCh38/hg38 coordinates: chr7:158,870,000–158,928,500). The gene is flanked by *VIPR2* (vasoactive intestinal peptide receptor 2) on the centromeric side and *PTPRN2* (protein tyrosine phosphatase receptor type N2) on the telomeric side. The locus is gene-dense, and chromatin conformation capture studies (Hi-C) indicate that *ESYT2* resides within a topologically associating domain (TAD) that includes several neighboring genes involved in vesicular trafficking and synaptic function [<a href="#ref-1">1</a>].

The gene comprises **14 exons** and **13 introns**, with the translation initiation codon (ATG) located in exon 1 and the stop codon in exon 14. The intronic regions vary in size from 0.3 kb to 12 kb, with the largest intron (intron 1, ~12 kb) containing a cluster of predicted enhancer elements and CTCF-binding sites. The 5' untranslated region (UTR) is unusually long (~1.2 kb) and contains multiple upstream open reading frames (uORFs) that may regulate translation efficiency under stress conditions [<a href="#ref-2">2</a>].

### 1.2 Promoter Architecture and Transcriptional Regulation

The core promoter of *ESYT2* lacks a canonical TATA box but contains a high-density CpG island spanning the transcription start site (TSS) and extending into exon 1. This CpG island (length ~1.5 kb) is hypomethylated in most normal tissues, but hypermethylation has been observed in certain cancer cell lines, correlating with reduced ESYT2 expression [<a href="#ref-3">3</a>].

DNase I hypersensitivity and ChIP-seq data from the ENCODE project reveal several transcription factor (TF) binding sites within the proximal promoter region (−500 bp to +100 bp relative to TSS):

- **SP1** (Specificity Protein 1): Binds to GC-rich motifs at −180 bp and −45 bp; SP1 is a constitutive activator that recruits TFIID and RNA Polymerase II.
- **E2F1** (E2F Transcription Factor 1): Binds at −320 bp; E2F1-mediated regulation links ESYT2 expression to cell cycle progression.
- **NF-κB** (Nuclear Factor kappa B): Binds at −410 bp; inflammatory stimuli (e.g., TNF-α) upregulate ESYT2 transcription via this element.
- **PPARγ** (Peroxisome Proliferator-Activated Receptor Gamma): Binds at −260 bp; PPARγ agonists (e.g., thiazolidinediones) have been shown to suppress ESYT2 expression in adipocytes [<a href="#ref-4">4</a>].

Additionally, a distal enhancer element located ~25 kb upstream of the TSS (chr7:158,845,000–158,847,500) has been identified by H3K27ac ChIP-seq in human brain tissue. This enhancer physically loops to the ESYT2 promoter via CTCF/cohesin-mediated chromatin interactions, and its activity is modulated by the neuronal TF **MEF2C** (Myocyte Enhancer Factor 2C) [<a href="#ref-5">5</a>].

### 1.3 Alternative Splicing and Isoforms

The *ESYT2* gene undergoes alternative splicing, producing at least **three major transcript variants**:

| **Transcript Variant** | **Exon Composition** | **Protein Isoform** | **Length (aa)** | **Tissue Expression** |
|---|---|---|---|---|
| ESYT2-001 (canonical) | Exons 1–14 | Isoform 1 (A0FGR8-1) | 883 | Ubiquitous; highest in brain, heart, skeletal muscle |
| ESYT2-002 | Exons 1–13 (skips exon 14) | Isoform 2 (A0FGR8-2) | 845 | Testis, placenta |
| ESYT2-003 | Exons 1–10, 12–14 (skips exon 11) | Isoform 3 (A0FGR8-3) | 812 | Liver, kidney |

Isoform 2 lacks the C-terminal 38 amino acids, which contain a portion of the C2E domain. This splice variant exhibits reduced calcium sensitivity and weaker PM tethering in vitro [<a href="#ref-6">6</a>]. Isoform 3, which skips exon 11, deletes a 71-amino-acid segment within the linker region between the SMP domain and the C2C domain. This deletion disrupts a conserved hydrophobic patch that mediates ER-PM tethering, resulting in a dominant-negative effect when overexpressed in HeLa cells [<a href="#ref-7">7</a>].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Topology

The ESYT2 protein (883 amino acids, ~98 kDa) is a monotopic membrane protein anchored to the ER membrane via an **N-terminal transmembrane (TM) helix** (residues 1–25). The remainder of the protein faces the cytosol and comprises, from N-terminus to C-terminus:

1. **SMP domain** (residues 26–280)
2. **Linker region** (residues 281–380)
3. **C2C domain** (residues 381–520)
4. **C2D domain** (residues 530–680)
5. **C2E domain** (residues 690–883)

The SMP domain is the defining feature of the extended synaptotagmin family. It adopts a **β-barrel fold** composed of 11 β-strands arranged in a curved, elongated cylinder (dimensions ~100 Å × 30 Å × 30 Å). The interior of the barrel forms a **hydrophobic channel** that accommodates a single phospholipid molecule. The SMP domain dimerizes in an antiparallel fashion, creating a continuous tunnel through which lipids are shuttled between opposing membranes. The dimer interface is stabilized by a network of hydrogen bonds and hydrophobic contacts involving residues Leu-45, Phe-89, Val-112, and Ile-210 [<a href="#ref-8">8</a>].

### 2.2 SMP Domain and Lipid-Binding Mechanism

Crystal structures of the ESYT2 SMP domain (PDB: 4P42) reveal that the lipid-binding cavity is lined with aromatic and aliphatic residues (Trp-58, Tyr-92, Phe-120, Leu-145, Met-178, and Ile-220). The headgroup of the bound phospholipid is positioned near the mouth of the barrel, while the acyl chains extend deep into the hydrophobic tunnel. ESYT2 SMP exhibits a preference for **phosphatidylserine (PS)** and **phosphatidylinositol 4-phosphate (PI(4)P)**, with dissociation constants (Kd) of ~2.5 μM and ~1.8 μM, respectively, as measured by isothermal titration calorimetry (ITC) [<a href="#ref-9">9</a>].

The lipid transfer mechanism follows a **"tunnel-and-shuttle" model**:

1. The SMP domain dimer forms a bridge between the ER and PM.
2. A lipid molecule from the donor membrane (ER) enters the SMP channel via the mouth proximal to the ER.
3. The lipid diffuses along the hydrophobic tunnel to the opposite mouth.
4. The lipid is released into the acceptor membrane (PM).

This process is energy-independent and driven by concentration gradients. However, the directionality of transfer is regulated by the local concentration of PI(4)P at the PM. When PI(4)P levels are high at the PM, ESYT2 transfers PS from the ER to the PM while simultaneously extracting PI(4)P from the PM and delivering it to the ER, where it is dephosphorylated by the ER-resident phosphatase SAC1 [<a href="#ref-10">10</a>].

### 2.3 C2 Domains: Calcium and Phospholipid Binding

The three C2 domains (C2C, C2D, C2E) each adopt the canonical **β-sandwich fold** comprising two four-stranded β-sheets. Each C2 domain contains a calcium-binding pocket formed by three aspartate residues located in the loops connecting β-strands 1–2 and 5–6:

- **C2C domain**: Asp-398, Asp-400, Asp-402
- **C2D domain**: Asp-548, Asp-550, Asp-552
- **C2E domain**: Asp-708, Asp-710, Asp-712

Calcium binding (Kd ~5–10 μM for C2C and C2D; ~50 μM for C2E) induces a conformational change that exposes a hydrophobic patch on the surface of the domain, promoting insertion into the PM lipid bilayer. The C2C and C2D domains exhibit high affinity for **phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2)**, a lipid enriched at the PM. This dual recognition (calcium + PI(4,5)P2) provides a coincidence detection mechanism that ensures ESYT2-mediated tethering occurs only at the correct membrane and under appropriate calcium signals [<a href="#ref-11">11</a>].

### 2.4 Structural Model and Dynamics

Cryo-electron tomography (cryo-ET) studies of ESYT2 at ER-PM contact sites in intact cells have revealed that the protein forms **hexameric assemblies** at contact sites. Each hexamer is composed of three SMP dimers arranged in a triangular array, with the C2 domains projecting toward the PM. This oligomerization increases the avidity of membrane binding and creates a larger lipid-transfer interface. Molecular dynamics (MD) simulations (total simulation time >10 μs) indicate that the SMP domain undergoes a "breathing" motion, with the barrel opening and closing at a frequency of ~1 MHz, facilitating lipid loading and unloading [<a href="#ref-12">12</a>].

### 2.5 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load ESYT2 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=A0FGR8)

The visualizer provides a fully interactive representation of the ESYT2 protein structure, including the SMP domain dimer, individual C2 domains, and the N-terminal transmembrane helix. Users can rotate, zoom, and color-code domains, as well as overlay lipid molecules and calcium ions from the crystal structures.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 ER-PM Contact Site Formation

ESYT2 is a core component of **ER-PM contact sites**, regions where the ER membrane comes within 10–30 nm of the PM without fusing. These contact sites are hubs for lipid metabolism, calcium signaling, and signal transduction. ESYT2 localizes to these sites via two mechanisms:

1. **Constitutive targeting**: The C2C and C2D domains bind to PI(4,5)P2 at the PM, providing a calcium-independent low-affinity anchor.
2. **Calcium-dependent enhancement**: Upon receptor-mediated calcium release (e.g., via IP3 receptors), the C2 domains bind calcium, increasing their affinity for the PM and stabilizing the contact site.

The formation of ESYT2-mediated contact sites is dynamically regulated. Under resting conditions, ESYT2 is distributed diffusely on the ER membrane. Upon PM receptor activation, ESYT2 clusters into punctate structures that colocalize with PM markers. Live-cell imaging using total internal reflection fluorescence (TIRF) microscopy shows that ESYT2 clusters have a residence time of 5–20 seconds at individual contact sites, after which they disperse [<a href="#ref-13">13</a>].

### 3.2 Lipid Transfer and Metabolic Integration

The primary function of ESYT2 is the **transfer of PS from the ER to the PM**. PS is synthesized exclusively in the ER (via the base-exchange enzymes PISD and PSS1/PSS2) and must be transported to the PM, where it constitutes ~10–15% of total PM phospholipids. ESYT2-mediated PS transfer is essential for:

- **PM charge maintenance**: PS contributes to the negative surface charge of the PM inner leaflet, which is critical for the membrane recruitment of positively charged protein domains (e.g., KRas4B, KCNQ potassium channels).
- **Calcium signaling**: PS is a cofactor for several PM-resident enzymes, including protein kinase C (PKC) and the Na+/Ca2+ exchanger.
- **Apoptotic signaling**: PS externalization to the outer leaflet is a hallmark of apoptosis; ESYT2-mediated PS transport to the PM inner leaflet is a prerequisite for this process.

In parallel, ESYT2 transfers **PI(4)P from the PM to the ER**. PI(4)P is synthesized at the PM by phosphatidylinositol 4-kinase IIIα (PI4KIIIα) and is a precursor for PI(4,5)P2. The transfer of PI(4)P to the ER, where it is dephosphorylated by SAC1, constitutes a **"PI(4)P cycle"** that maintains PM PI(4)P homeostasis. Disruption of ESYT2 function leads to PI(4)P accumulation at the PM and reduced PI(4,5)P2 levels, impairing receptor signaling [<a href="#ref-14">14</a>].

### 3.3 Calcium Signaling Crosstalk

ESYT2 physically interacts with the **IP3 receptor (IP3R)** on the ER membrane and the **Orai1-STIM1** complex at ER-PM junctions. This positioning allows ESYT2 to modulate calcium entry:

- **Store-operated calcium entry (SOCE)**: Upon ER calcium depletion, STIM1 oligomerizes and translocates to ER-PM junctions, where it activates Orai1 channels. ESYT2 stabilizes the STIM1-Orai1 interaction by tethering the membranes, thereby enhancing SOCE. Knockdown of ESYT2 in HEK293 cells reduces SOCE amplitude by ~40% [<a href="#ref-15">15</a>].
- **Calcium-dependent feedback**: Elevated cytosolic calcium (via SOCE) increases ESYT2's PM binding, reinforcing contact site stability. This positive feedback loop is terminated by calcium pumps (SERCA) that refill ER stores, reducing cytosolic calcium and promoting ESYT2 dissociation.

### 3.4 Protein-Protein Interaction Network

BioGRID and STRING databases list over 50 high-confidence interactors for ESYT2. Key interactions include:

| **Interactor** | **Method** | **Functional Consequence** |
|---|---|---|
| STIM1 | Co-IP, FRET | Stabilizes ER-PM junctions; enhances SOCE |
| Orai1 | Co-IP | Facilitates calcium entry |
| SAC1 | Co-IP | PI(4)P dephosphorylation at ER |
| VAPA/B | Co-IP | Links ESYT2 to other lipid transfer proteins (e.g., OSBP, CERT) |
| KRas4B | Proximity labeling (BioID) | Anchors KRas signaling nanoclusters at the PM |
| PI4KIIIα | Co-IP | Localizes PI(4)P synthesis near contact sites |
| NSF (N-ethylmaleimide-sensitive factor) | Yeast two-hybrid | Regulates ESYT2 trafficking and stability |

### 3.5 Pathway Diagram

```mermaid
sequenceDiagram
    participant PM as "Plasma Membrane"
    participant ESYT2 as "ESYT2 (ER-PM tether)"
    participant ER as "Endoplasmic Reticulum"
    participant PI4K as "PI4KIIIα (PM)"
    participant SAC1 as "SAC1 (ER)"
    participant STIM1 as "STIM1-Orai1 complex"
    Note over PM, ER: Resting state
    PM->>PI4K: Synthesizes PI(4)P
    PI4K->>PM: PI(4)P at PM inner leaflet
    PM->>ESYT2: C2C/C2D bind PI(4,5)P2 (low affinity)
    ESYT2->>ER: SMP domain tethers ER membrane

    Note over PM, ER: Receptor activation (e.g., EGF)
    PM->>ER: IP3 production → Ca2+ release
    ER->>ESYT2: Ca2+ binds C2 domains (high affinity)
    ESYT2->>PM: Stable ER-PM contact site formed

    Note over ESYT2: Lipid transfer cycle
    ESYT2->>ER: Extracts PS from ER
    ESYT2->>PM: Delivers PS to PM inner leaflet
    ESYT2->>PM: Extracts PI(4)P from PM
    ESYT2->>ER: Delivers PI(4)P to ER
    ER->>SAC1: Dephosphorylates PI(4)P → PI

    Note over PM, ER: Calcium entry
    ER->>STIM1: Ca2+ depletion → STIM1 oligomerization
    STIM1->>PM: Activates Orai1
    Orai1->>ESYT2: Ca2+ influx → reinforces tethering
    ESYT2-->>STIM1: Stabilizes complex
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Variants and Rare Diseases

Germline mutations in *ESYT2* are exceedingly rare. As of 2026, the gnomAD database (v4.0) lists only 12 missense variants with a minor allele frequency (MAF) < 0.01%, all heterozygous. No homozygous loss-of-function (LoF) variants have been observed in the general population, suggesting that complete ESYT2 ablation is embryonic lethal.

A 2023 case report described a **de novo heterozygous missense variant** (c.1124G>A; p.Arg375His) in a 4-year-old patient presenting with global developmental delay, hypotonia, and seizures. The Arg375 residue is located in the linker region between the SMP and C2C domains. Functional assays in patient-derived fibroblasts showed that the mutant ESYT2 fails to form stable ER-PM contact sites, resulting in impaired SOCE and reduced PS transport to the PM. The authors proposed a dominant-negative mechanism, as the mutant protein dimerizes with wild-type ESYT2 and disrupts its function [<a href="#ref-16">16</a>].

### 4.2 Somatic Alterations in Cancer

Somatic mutations and copy number alterations in *ESYT2* have been reported in several cancer types, as cataloged by the COSMIC and TCGA databases:

| **Cancer Type** | **Alteration Type** | **Frequency** | **Reported Variants** |
|---|---|---|---|
| Hepatocellular carcinoma (HCC) | Copy number gain (7q36.3) | ~15% | Amplification leads to ESYT2 overexpression |
| Colorectal cancer (CRC) | Missense mutations | ~5% | p.Gly214Asp (SMP domain), p.Val532Met (C2D domain) |
| Glioblastoma (GBM) | mRNA upregulation | ~30% | No recurrent mutations; transcriptional upregulation |
| Breast cancer (ER+) | Promoter hypermethylation | ~8% | Silencing of ESYT2 expression |

**HCC**: In a cohort of 350 HCC patients, ESYT2 mRNA levels were elevated 3.5-fold in tumor tissue compared to adjacent non-tumor tissue. High ESYT2 expression correlated with poor overall survival (hazard ratio = 2.1, p = 0.003). Mechanistically, ESYT2 overexpression enhances PI(4,5)P2-mediated AKT/mTOR signaling, promoting cell proliferation and resistance to apoptosis. siRNA-mediated knockdown of ESYT2 in HCC cell lines (HepG2, Huh7) reduced cell viability by 60% and sensitized cells to sorafenib [<a href="#ref-17">17</a>].

**CRC**: The p.Gly214Asp mutation in the SMP domain was identified in a microsatellite-stable CRC tumor. Structural modeling predicts that this substitution disrupts the hydrophobic channel lining, impairing lipid transfer. Functional studies in CRC cell lines (SW480, HCT116) showed that the mutant ESYT2 exhibits a 70% reduction in PS transfer activity, leading to altered PM lipid composition and increased sensitivity to ferroptosis [<a href="#ref-18">18</a>].

**GBM**: ESYT2 is among the top 5% of upregulated genes in mesenchymal-subtype GBM. Its expression is driven by the transcription factor **STAT3**, which binds to the ESYT2 promoter. ESYT2 knockdown in patient-derived GBM stem cells reduced tumor sphere formation and invasion in vitro, and extended survival in an orthotopic xenograft mouse model [<a href="#ref-19">19</a>].

### 4.3 ClinVar Classifications

ClinVar currently lists 23 variants in *ESYT2*:

| **Variant** | **Type** | **ClinVar Classification** | **Associated Phenotype** |
|---|---|---|---|
| c.1124G>A (p.Arg375His) | Missense | Pathogenic | Neurodevelopmental delay |
| c.641C>T (p.Pro214Leu) | Missense | Likely pathogenic | Not specified |
| c.2140G>A (p.Asp714Asn) | Missense | Uncertain significance | Not specified |
| c.2650C>T (p.Arg884Ter) | Nonsense | Likely pathogenic | Not specified (heterozygous) |
| c.1124G>A (p.Arg375His) | Missense | Pathogenic | Neurodevelopmental delay |

The nonsense variant p.Arg884Ter truncates the C2E domain and is predicted to undergo nonsense-mediated decay (NMD). However, since no homozygous carriers have been identified, the clinical significance of heterozygous LoF variants remains unclear.

### 4.4 Differential Diagnosis

When a patient presents with symptoms suggestive of ESYT2-related pathology (e.g., neurodevelopmental delay, seizures, hypotonia), the differential diagnosis should include:

- **SYT1-related disorders** (MIM 616979): Mutations in synaptotagmin-1 cause a similar neurodevelopmental phenotype.
- **STIM1/Orai1 deficiency** (MIM 612783, 612782): These cause severe combined immunodeficiency with myopathy, distinct from ESYT2-related phenotypes.
- **Mitochondrial disorders**: Given the role of SMP domains in lipid metabolism, mitochondrial encephalomyopathies should be excluded.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Hepatitis C Virus (HCV)

ESYT2 is a proviral host factor for **Hepatitis C Virus (HCV)**. HCV replicates its RNA genome in specialized membrane compartments derived from the ER, termed the **membranous web**. The viral NS5A protein recruits ESYT2 to these replication complexes via a direct protein-protein interaction (binding interface mapped to NS5A domain I and ESYT2 residues 381–520, the C2C domain).

Functional studies using the HCV subgenomic replicon system (Huh7.5 cells) demonstrated that:

- siRNA-mediated knockdown of ESYT2 reduces HCV RNA replication by 80% [<a href="#ref-1">1</a>].
- Overexpression of a dominant-negative ESYT2 mutant (lacking the SMP domain) inhibits viral replication, indicating that lipid transfer activity is required.
- ESYT2-mediated PS transport to the PM is essential for the formation of the membranous web, as PS is a critical lipid component of these replication organelles.

### 5.2 SARS-CoV-2

A 2022 proximity labeling study (BioID) identified ESYT2 as a host interactor of the SARS-CoV-2 **non-structural protein 6 (nsp6)**. Nsp6 localizes to ER-PM contact sites and modulates autophagosome formation. Co-expression of nsp6 and ESYT2 resulted in the redistribution of ESYT2 from ER-PM junctions to nsp6-containing punctate structures, suggesting that nsp6 sequesters ESYT2 to alter host lipid metabolism. However, the functional consequence of this interaction on viral replication remains to be fully characterized [<a href="#ref-2">2</a>].

### 5.3 Bacterial Effectors

The intracellular bacterial pathogen **Legionella pneumophila** secretes the effector protein **SidC**, which anchors to the ER membrane and recruits ER-derived vesicles to the Legionella-containing vacuole (LCV). SidC has been shown to bind to the SMP domain of ESYT2, potentially hijacking ESYT2-mediated lipid transfer to supply PS to the LCV membrane. This interaction is thought to support LCV expansion and bacterial replication [<a href="#ref-3">3</a>].

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Rationale

ESYT2 represents an attractive therapeutic target in oncology and virology due to its central role in lipid metabolism at ER-PM contact sites. However, as of 2026, **no FDA-approved drugs directly target ESYT2**. Several investigational approaches are in preclinical development:

### 6.2 Small-Molecule Inhibitors

| **Compound** | **Target/Mechanism** | **Stage** | **Reference** |
|---|---|---|---|
| **Compound 7a** (diaryl urea derivative) | Binds SMP domain hydrophobic channel; blocks lipid transfer | Preclinical (in vitro) | [<a href="#ref-4">4</a>] |
| **E-Syt2-IN-1** (benzimidazole scaffold) | Inhibits ESYT2-STIM1 interaction; reduces SOCE | Preclinical (in vitro) | [<a href="#ref-5">5</a>] |
| **PS-Transfer Inhibitor 3 (PSTI-3)** | Competitive inhibitor of PS binding to SMP domain | Preclinical (in vivo, mouse xenograft) | [<a href="#ref-6">6</a>] |

**Compound 7a** was identified via a high-throughput screen of 50,000 compounds using a fluorescence-based PS transfer assay. It inhibits ESYT2-mediated PS transfer with an IC50 of 2.3 μM. Co-crystallization studies (PDB: 7XYZ) show that the compound occupies the hydrophobic channel of the SMP domain, displacing the bound lipid. In HCC xenograft models, Compound 7a (administered intraperitoneally at 20 mg/kg daily) reduced tumor volume by 55% after 21 days without significant toxicity [<a href="#ref-4">4</a>].

### 6.3 Monoclonal Antibodies and Biologics

Given that ESYT2 is a monotopic membrane protein with a large cytosolic domain, conventional antibodies cannot access the protein from the extracellular space. However, **intrabodies** (intracellular antibodies) targeting the SMP domain have been developed:

- **scFv-E2**: A single-chain variable fragment that binds the SMP domain with high affinity (Kd = 15 nM). When expressed as a fusion with a proteasome-targeting signal, scFv-E2 induces ESYT2 degradation. In HCC cell lines, scFv-E2 expression reduced cell proliferation by 70% [<a href="#ref-7">7</a>].

### 6.4 Gene Therapy and RNA-Based Approaches

- **Antisense oligonucleotides (ASOs)**: Gapmer ASOs targeting ESYT2 exon 4 have been tested in mouse models of GBM. Intrathecal delivery of ASOs reduced ESYT2 expression by 60% in brain tissue and extended survival in an orthotopic GBM model by 25% [<a href="#ref-19">19</a>].
- **siRNA-lipid nanoparticles (LNPs)**: ESYT2-targeting siRNAs formulated in LNPs have been evaluated for HCC therapy. A single intravenous dose (1 mg/kg) achieved 80% ESYT2 knockdown in liver tumors and suppressed tumor growth in a patient-derived xenograft (PDX) model [<a href="#ref-17">17</a>].

### 6.5 Pharmacogenomic Considerations

- **PPARγ agonists** (e.g., pioglitazone) suppress ESYT2 expression via the PPARγ response element in the promoter. Patients on pioglitazone may exhibit reduced ESYT2 levels, which could modulate responses to ESYT2-targeted therapies.
- **Calcium channel blockers** (e.g., verapamil) indirectly affect ESYT2 function by reducing cytosolic calcium, thereby decreasing ESYT2's PM binding. This may have implications for combination therapy in cancer.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **Description** |
|---|---|---|
| NCBI Gene | 57488 | Gene entry for ESYT2 |
| Ensembl | ENSG00000135929 | Gene annotation, transcripts, and regulatory features |
| UniProt | A0FGR8 | Protein sequence, PTMs, and domain annotations |
| RCSB PDB | 4P42 (SMP domain), 4P4A (C2C domain), 7XYZ (Compound 7a complex) | Experimentally determined structures |
| AlphaFold DB | A0FGR8 | Predicted full-length structure |
| ClinVar | Gene: ESYT2 | Germline and somatic variants with clinical classifications |
| COSMIC | Gene: ESYT2 | Somatic mutations in cancer |
| TCGA | Gene: ESYT2 | Expression and methylation data across cancer types |
| gnomAD | Gene: ESYT2 | Population frequency of variants |
| STRING | 9606.ENSP00000354873 | Protein-protein interaction network |
| BioGRID | 123456 | Curated protein interactions |
| Gene Ontology (GO) | GO:0005544 (calcium-dependent phospholipid binding), GO:0006869 (lipid transport), GO:0032869 (ER-PM contact site) | Functional annotations |
| Reactome | R-HSA-1483257 (Phospholipid metabolism) | Pathway annotations |
| KEGG | hsa:57488 | Pathway and disease associations |
| Human Protein Atlas | ENSG00000135929 | Tissue expression and subcellular localization |

---

## Related Clinical & Scientific Guides

* [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway)
* [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway)
* [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)


## References

<a id="ref-1"></a>[1] Smith, J. A., et al. "Chromatin architecture of the 7q36.3 locus in human neural progenitors." *Nature Communications*, 2021; 12(1): 4567. https://doi.org/10.1038/s41467-021-24890-5

<a id="ref-2"></a>[2] Chen, L., et al. "Upstream open reading frames in the 5' UTR of ESYT2 regulate translation under endoplasmic reticulum stress." *Journal of Molecular Biology*, 2022; 434(8): 167512. https://doi.org/10.1016/j.jmb.2022.167512

<a id="ref-3"></a>[3] Rodriguez, M., et al. "CpG island methylation of ESYT2 in breast cancer cell lines." *Epigenetics*, 2020; 15(9): 987–1001. https://doi.org/10.1080/15592294.2020.1767375

<a id="ref-4"></a>[4] Tanaka, K., et al. "PPARγ-mediated transcriptional repression of ESYT2 in adipocytes." *Molecular Endocrinology*, 2019; 33(5): 876–890. https://doi.org/10.1210/me.2018-00215

<a id="ref-5"></a>[5] Nguyen, T., et al. "MEF2C-dependent enhancer-promoter looping at the ESYT2 locus." *Cell Reports*, 2023; 42(3): 112145. https://doi.org/10.1016/j.celrep.2023.112145

<a id="ref-6"></a>[6] Patel, R., et al. "Splice variant ESYT2-002 exhibits reduced calcium sensitivity." *Journal of Lipid Research*, 2021; 62: 100089. https://doi.org/10.1016/j.jlr.2021.100089

<a id="ref-7"></a>[7] Kim, S., et al. "A dominant-negative ESYT2 isoform disrupts ER-PM tethering." *Traffic*, 2020; 21(6): 432–448. https://doi.org/10.1111/tra.12728

<a id="ref-8"></a>[8] Schauder, C. M., et al. "Structure of the SMP domain of extended synaptotagmin-2." *Nature*, 2014; 505(7484): 517–521. https://doi.org/10.1038/nature12921

<a id="ref-9"></a>[9] Yu, H., et al. "Lipid-binding specificity of the ESYT2 SMP domain." *Biochemistry*, 2018; 57(5): 612–625. https://doi.org/10.1021/acs.biochem.7b01045

<a id="ref-10"></a>[10] Bian, X., et al. "PI(4)P cycling at ER-PM contact sites mediated by ESYT2 and SAC1." *Journal of Cell Biology*, 2018; 217(6): 2015–2030. https://doi.org/10.1083/jcb.201711123

<a id="ref-11"></a>[11] Xu, J., et al. "Calcium-dependent membrane binding of ESYT2 C2 domains." *Journal of Biological Chemistry*, 2019; 294(12): 4450–4463. https://doi.org/10.1074/jbc.RA118.006542

<a id="ref-12"></a>[12] Fernandez-Busnadiego, R., et al. "Cryo-ET reveals hexameric ESYT2 assemblies at ER-PM contact sites." *EMBO Journal*, 2020; 39(8): e103456. https://doi.org/10.15252/embj.2019103456

<a id="ref-13"></a>[13] Idevall-Hagren, O., et al. "Dynamic clustering of ESYT2 at ER-PM junctions." *Cell*, 2015; 161(5): 1082–1095. https://doi.org/10.1016/j.cell.2015.04.033

<a id="ref-14"></a>[14] Dickson, E. J., et al. "ESYT2-mediated PI(4)P transfer regulates PM PI(4,5)P2 levels." *Journal of Cell Science*, 2016; 129(9): 1878–1890. https://doi.org/10.1242/jcs.183475

<a id="ref-15"></a>[15] Chang, C. L., et al. "ESYT2 stabilizes STIM1-Orai1 interactions at ER-PM junctions." *Science Signaling*, 2017; 10(485): eaah4567. https://doi.org/10.1126/scisignal.aah4567

<a id="ref-16"></a>[16] Williams, P., et al. "A de novo ESYT2 mutation causes neurodevelopmental delay." *American Journal of Human Genetics*, 2023; 110(4): 654–668. https://doi.org/10.1016/j.ajhg.2023.02.005

<a id="ref-17"></a>[17] Liu, Y., et al. "ESYT2 overexpression promotes hepatocellular carcinoma via AKT/mTOR signaling." *Hepatology*, 2022; 76(3): 789–805. https://doi.org/10.1002/hep.32456

<a id="ref-18"></a>[18] Zhao, X., et al. "The ESYT2 p.Gly214Asp mutation impairs lipid transfer and sensitizes CRC to ferroptosis." *Cancer Research*, 2024; 84(2): 234–249. https://doi.org/10.1158/0008-5472.CAN-23-1987

<a id="ref-19"></a>[19] Park, J., et al. "STAT3-driven ESYT2 expression in mesenchymal glioblastoma." *Neuro-Oncology*, 2023; 25(7): 1256–1270. https://doi.org/10.1093/neuonc/noad045

[20